LCZ-Mont OD Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated for the management of allergic conditions. Levocetirizine is a selective, non-sedating antihistamine that competitively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast is a leukotriene receptor antagonist that blocks the cysteinyl leukotriene receptor CysLT1, which plays a critical role in the pathophysiology of asthma and allergic rhinitis by mediating bronchoconstriction, mucus secretion, and inflammation. The combination of these two agents provides a synergistic effect, addressing both histamine-mediated and leukotriene-mediated pathways, resulting in improved control of allergic symptoms. LCZ-Mont OD Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management. The once-daily dosing enhances patient compliance. It is generally well-tolerated; however, potential side effects include headache, fatigue, dry mouth, and gastrointestinal disturbances. Use with caution in patients with hepatic or renal impairment. Consultation with a healthcare professional is recommended before initiating therapy to ensure appropriate use and monitoring.